Low dose oral methotrexate treatment of multiple sclerosis: a pilot study.
An 18-month double-blind treatment of multiple sclerosis with low dose oral methotrexate showed it to be well tolerated and suggested effectiveness in exacerbating-remitting MS but not in the exacerbating progressive and chronic progressive stages.
Currier
R D
RD
Department of Neurology, University of Mississippi Medical Center, Jackson 39216.
Haerer
A F
AF
Meydrech
E F
EF
D000284:Administration, Oral; D000328:Adult; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D008297:Male; D008727:Methotrexate / Q000008:administration & dosage*; D009103:Multiple Sclerosis / Q000188:drug therapy*; D010919:Placebos
D010919:Placebos; D008727:Methotrexate